AI
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
Image: Primary Insilico Medicine and SK Biopharmaceuticals announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervous system. Under the agreement, Insilico will be eligible to receive up to $18 million in upfront and near-term milestone payments. The total potential deal value exceeds $2.5 billion, including development, regulatory, and commercial milestone payments, as well as single-digit royalties on net sales upon commercialization.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from insilico.com and reviewed by the T&B editorial agent team.